Why AndroGel (testosterone topical) Causes Transfer to Women and Children: The Mechanism Explained

At a glance

• Incidence of documented secondary transfer: Case series and post-marketing data prompted the FDA to add a Black Box Warning in 2009; pediatric virilization cases were reported with AndroGel 1% in clinical use
• Typical timeline to virilization signs in children: Weeks to months of repeated low-dose exposure; clitoral or penile enlargement, pubic hair, and aggressive behavior have appeared within 4 to 8 weeks in reported cases
• Typical timeline to virilization signs in women: Acne, clitoral enlargement, voice changes, and menstrual irregularity can develop within 4 to 12 weeks of repeated contact
• First-line management: Strict application-site covering, immediate post-application handwashing, and a no-skin-contact window of at least 2 hours (or until the site is washed)
• When to escalate: Any sign of premature pubic hair, clitoral or penile growth, acne, or unexplained aggressive behavior in a child with household TRT exposure warrants same-day pediatric endocrinology referral
• When to discontinue AndroGel: If household exposure cannot be reliably prevented, the prescriber should consider switching to a non-topical testosterone formulation such as injectable or subcutaneous pellet

How Testosterone Gets From the Tube to Another Person's Body

AndroGel is formulated as a hydroalcoholic gel. The alcohol carrier evaporates rapidly after application, typically within 5 to 10 minutes, leaving behind a film of testosterone embedded in the uppermost layers of the stratum corneum. This film does not disappear. Studies using labeled testosterone have shown that the skin depot persists for at least 4 to 6 hours after application, slowly releasing hormone both into the user's own dermal vasculature and outward, where it remains available for transfer.

When another person's skin presses against that film, a straightforward partition process occurs. Testosterone is a lipophilic steroid with a log P of approximately 3.3. It partitions readily from the stratum corneum of the applicator into the stratum corneum of whoever makes contact, following the concentration gradient. The higher the residue on the treated site, the greater the driving force for transfer.

The Phase III pharmacokinetic study supporting AndroGel 1% approval found that direct skin-to-skin contact transferred enough testosterone to raise serum levels in female partners to clearly supraphysiological concentrations. Forearm-to-forearm contact for just 15 minutes while the site was uncovered produced a mean increase in female serum testosterone that reached roughly five times baseline. Covering the application site with a cotton shirt reduced transfer by approximately 96 percent in the same model.

Why Children Are Especially Vulnerable

Body weight is the key variable. A child weighing 20 kilograms requires only a fraction of the testosterone dose needed to saturate androgen receptors in an adult. Even a small transfer event, one that would produce a barely detectable serum shift in an adult woman, can push a prepubertal child into pharmacologically active androgen exposure.

The hypothalamic-pituitary-gonadal axis in prepubertal children is in a quiescent state. Androgen receptors in genital tissue, the adrenal glands, and the brain are fully functional but are not receiving gonadal steroid input. Exogenous testosterone binds those receptors directly and triggers downstream transcription of androgen-responsive genes. In genital tissue this means accelerated clitoromegaly or phallic growth. In bone, androgen-driven IGF-1 signaling accelerates epiphyseal maturation, compressing the window for linear growth. In the brain, androgen exposure during sensitive developmental windows can produce behavioral changes, particularly increased aggression.

FDA safety communications issued after the Black Box Warning described children who had developed pubic hair, clitoral enlargement, or advanced bone age after living in households where a caregiver used topical testosterone. In several cases the source of exposure was not recognized until the child underwent endocrine workup, because the contact had been incidental, a hug, sitting in a caregiver's lap, or touching an unwashed hand.

The Pharmacokinetics of Secondary Exposure

After transfer, testosterone crosses the recipient's skin barrier and enters the dermal capillary network. Because women and children have lower endogenous testosterone production, any exogenous increment produces a proportionally larger change in total serum levels. In adult women, normal total testosterone ranges from approximately 15 to 70 ng/dL. The AndroGel prescribing information and supporting pharmacokinetic data document that uncovered skin contact with a freshly applied dose can raise a female partner's testosterone to levels well above 100 ng/dL, which is sufficient to initiate androgenic gene transcription in target tissues.

Testosterone absorbed through skin bypasses the first-pass hepatic metabolism that attenuates orally administered androgens. It enters systemic circulation as free or albumin-bound testosterone, with a small fraction binding sex hormone-binding globulin. The free fraction is biologically active at the receptor level and drives the virilization cascade. The half-life of absorbed testosterone is short, roughly 10 to 100 minutes in plasma, but with daily re-exposure the cumulative tissue effect on hair follicles, clitoral stroma, vocal cords, and bone is progressive and, in some end-organs, partially irreversible.

Which Application Sites Carry the Highest Transfer Risk

AndroGel is labeled for application to the shoulders, upper arms, and abdomen. These are all areas likely to be touched during normal household contact. The shoulders and upper arms are particularly high-risk because they contact other people during embraces, and children are commonly carried against those surfaces. The hands are a secondary transfer vector. The prescribing information explicitly instructs users to wash hands with soap and water immediately after application, yet residue on palms and finger pads is a documented exposure route, particularly for infants and toddlers who are held, fed, or changed by the applicator.

The genitals and inner thigh are not recommended application sites, but scrotal testosterone formulations exist for other indications. Transfer risk from scrotal application during sexual contact is a separate clinical concern that applies specifically to female partners.

Practical Prevention: What Actually Works

Mechanistic understanding directly informs prevention. Because transfer depends on direct contact with the skin depot, any intervention that physically separates the depot from another person's skin interrupts the process.

Immediate handwashing removes residue from the palms and fingers before those surfaces contact children or partners. Soap and water are effective. Alcohol-based hand sanitizers are less effective because they may partially solubilize and redistribute gel rather than removing it.

Clothing coverage is the highest-impact single intervention. A cotton T-shirt over the application site reduces transfer by approximately 96 percent, as documented in controlled pharmacokinetic testing. The clothing acts as both a physical barrier and an absorbent layer that binds residual testosterone away from the skin surface.

Time reduces but does not eliminate risk. After 2 hours with the site uncovered, transfer is substantially lower than immediately post-application, but residue is measurable for up to 6 hours. Washing the site with soap and water before contact eliminates the risk more reliably than waiting.

Swimming or showering before planned contact, rather than after application, was evaluated in pharmacokinetic sub-studies of the AndroGel development program and found to remove most surface-layer testosterone without meaningfully reducing systemic absorption, because deeper dermal layers had already taken up the dose.

For households where reliable prevention is not feasible, including those with infants, toddlers, or pregnant women, clinical guidelines from the Endocrine Society suggest that prescribers consider non-topical testosterone delivery systems. Injectable testosterone cypionate or enanthate, subcutaneous pellets, and intranasal testosterone formulations carry no secondary transfer risk.

What Virilization Signs to Watch For

Any household member with repeated AndroGel exposure should be monitored for the following:

In prepubertal children: pubic or axillary hair appearing before the expected age of puberty, clitoral enlargement in girls, penile growth beyond expected developmental stage in boys, acne, body odor inconsistent with age, and behavior changes including increased aggression. Serum total testosterone and bone age X-ray are the appropriate initial investigations.

In women: new or worsening acne, increased body or facial hair, clitoral enlargement, deepening voice, menstrual irregularity, or scalp hair thinning in a male-pattern distribution. Serum total and free testosterone should be measured and compared with the patient's baseline or the normal female range.

In pregnant women: fetal virilization is an additional risk. Testosterone crosses the placenta. Any androgen exposure during the critical window of genital differentiation (approximately 8 to 13 weeks gestation) can produce ambiguous genitalia in a female fetus. Pregnant women should avoid all contact with AndroGel application sites.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wang C, et al. "Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men." Journal of Clinical Endocrinology and Metabolism. 2000. https://pubmed.ncbi.nlm.nih.gov/12629403/
• U.S. Food and Drug Administration. "AndroGel (testosterone gel) 1% Prescribing Information." 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s034lbl.pdf
• U.S. Food and Drug Administration. "FDA Drug Safety Communication: FDA warns about serious risks and the use of testosterone products." https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-use-testosterone-products-and-abuse
• Bhasin S, et al. "Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology and Metabolism. 2010. https://pubmed.ncbi.nlm.nih.gov/20525906/
• Stahlman J, et al. "Testosterone transfer to female partners and children following transdermal AndroGel application: effect of clothing and washing." Annals of Pharmacotherapy. 2012. https://pubmed.ncbi.nlm.nih.gov/22395246/